Business Context and Reporting Period
Palisade Bio, Inc. (PALI), a Delaware corporation, filed this Form 8-K on December 16, 2024, reporting events occurring on December 12 and 13, 2024. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapeutics.
Key Financial Metrics and Capital Structure
- Capital Raised: Net proceeds from the public offering were approximately $4.10 million after underwriting discounts and estimated offering expenses.
- Offering Structure: The company sold 158,000 Class A Units at $1.525 per unit and 3,120,688 Class B Units at $1.5249 per unit. Each unit consists of one share (or prefunded warrant) and one common warrant.
- Warrant Terms: Common warrants have an exercise price of $1.40 and expire five years from issuance. Prefunded warrants have an exercise price of $0.0001 and a perpetual term.
- Outstanding Shares: As of December 13, 2024, the company had 2,765,980 shares of common stock outstanding following the offering and exercise of certain prefunded warrants.
- Debt and Liquidity: The filing does not provide specific data on existing debt, cash flow, or liquidity positions outside of the new capital raised.
Material Changes and Agreements
- Underwriting Agreement: Entered into with Ladenburg Thalmann & Co. Inc. on December 12, 2024. Includes a 45-day overallotment option for up to 491,803 additional shares/warrants.
- Warrant Repricing: The company reduced the exercise price of 1,040,217 outstanding warrants held by a participating investor to $1.40 per share. These warrants expire between July 2027 and May 2031.
- Lock-Up Agreements: Executive officers and directors are subject to a 90-day lock-up period. A 180-day lock-up applies to variable rate transactions.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Funds will be used to fund the Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital.
- Trading Status: There is no trading market for the prefunded or common warrants, and the company does not intend to list them on any exchange.
- Risks: The filing notes standard indemnification liabilities to the underwriter and the dilutive effect of the new securities issued.
Investor Verification Checklist
- Verify the exact number of shares issued upon exercise of prefunded warrants included in the 2,765,980 outstanding share count.
- Confirm the status of the 45-day overallotment option and whether it was exercised.
- Review the specific terms of the warrant repricing agreement to understand the impact on existing shareholders.
- Monitor the timeline for the Phase 1 clinical trial of PALI-2108 to assess the burn rate of the $4.10 million raised.